Systemic lupus erythematosus (SLE) is considered the prototype of autoimmune diseases, the most complex autoimmune pathology and it is characterized by a wide range of immune processes, important antibodies production as well as an impressive spectrum of clinical manifestations. The great variety of lupus signs and symptoms caused difficulties in establishing well-defined classification criteria, as well as sustaining the clinical diagnosis.
( 1) However, important aspects of SLE disease are still incomplete acknowledged, like photosensitivity and vasculitis definition or optimal immunosuppression duration . ' '' (1) In 1962, American Rheumatism Association ( A RA ) C o m m i t t e e o n D i a g n o s i s a n d Therapeutic Criteria defined the first set of SLE classification criteria in 1971 and then published the status of the Criteria for the Classification of SLE . According to this (2) criteria, the pathology was classified as SLE when any or more than four out of fourteen l u p u s m a n i f e s t a t i o n s w e r e p r e s e n t simultaneously or successively, during any interval of follow-up . (2) The SLE criteria were revised in 1982, i n c o r p o r a t i n g t h e p r e l i m i n a r y S L E classification set in order to increase both sensitivity and specificity of the used items and the cutoff value used to define the disease. Therefore, important immunological parameters were included in the 1982 revised criteria for the classification of SLE, namely the antinuclear antibodies (ANAs), assessed by indirect immunofluorescence (IFI), as well as the antibodies to double-stranded DNA (anti-dsDNA) and anti-Sm antibodies. Some of the items referring to similar organ involvement were arranged in the same domain and also less specific characteristics were not included, like Raynaud phenomenon or alopecia . The 1982 revised SLE ( 3 ) classification criteria were tested in patients from 18 clinics and proved 96% for both sensitivity and specificity . ACR criteria. In their cohort of the 2012 SLICC criteria validation, the specificity was lower (84% vs. 96%) while the sensitivity was higher (97% vs. 83%) than the ACR criteria , but (5) further one meta-analysis found similar specificity (96% vs. 98%), but higher sensitivity (95% vs. 90%) when comparing the 2012 SLICC criteria with the 1997 ACR in adult patients , difference that was than show (6) in other research to be more evident in early disease patients . (7) In 2019, a joint initiative of European League counted for the final score. There is need of a total score equal or more than 10 points (out of a theoretical maximum 51 points) in order to fulfill the classification criteria (see Table 1 ).
The current system changed therefore the yes/no decision for clinical involvement to a point system in which only one manifestation for each domain, the one that is higher weighted, is counted . (8) A literature review as well as a meta- General Reviews systemic immune involvement, SLE included (9) . Therefore, such cases should be analyzed separately in clinical practice and the criteria should only be apply when there is clinical SLE suspicion.
The ANA evaluation was the first step in defining the new criteria set . This step was (8 9) , followed by literature review made to identify 21 candidate criteria , criteria reduction, (10) criteria definition and weighing based on their performance and, finally, analysis compared to already available SLE classification criteria, using a validation cohort including 696 SLE patients and 574 controls . In order to (8) determine However, the patients' inclusion was done from rheumatology centers and this might be a bias of selection as patients presenting initially to other specialties might have different disease patterns . For example, (11) arthritis might be more frequent in these patients than in those presenting in other specialties than rheumatology (pediatric SLE or dermatology with skin dominant disease)
In clinical practice, the classification criteria will perform differently in SLE population and moreover, each clinical case should be regarded upon all its aspects, remembering General Reviews 35 that available tools are proposed for classification, for use in research studies and not directly for patients' diagnosis. One recent analysis showed that for childhood-onset SLE, the specificity of 2012 SLICC criteria was better than that of the 2019 EULAR/ ACR at the first visit as well at one year (80.9% vs 67.4%, p=0.008 and 76.4% vs 58.4%, p = 0 . 0 0 1 , re s p e c t i v e l y ) , b u t s i m i l a r sensitivities. When the cut-off for defining the classification was moved from 10 to 13 points, the 2019 EULAR/ ACR criteria scored better . (12) Future studies will further test the usefulness of the new SLE classification criteria in routine clinical practice. 
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